'By no means are we de­terred': Seres' stock spi­rals af­ter PhII mi­cro­bio­me fail in ul­cer­a­tive col­i­tis

Al­most five years af­ter Seres Ther­a­peu­tics slammed in­to a Phase II fail­ure with its lead can­di­date, the mi­cro­bio­me pi­o­neer is re­port­ing an­oth­er mas­sive flop in ul­cer­a­tive col­i­tis. But like the last time, the com­pa­ny isn’t throw­ing in the tow­el just yet.

Pa­tients who took SER-287 — a con­sor­tia of bac­te­ria found in the gas­troin­testi­nal tracts of healthy in­di­vid­u­als — showed no dif­fer­ence in clin­i­cal re­mis­sion com­pared to those giv­en a place­bo, Seres said of the Phase IIb tri­al. The news sent the biotech’s shares $MCRB spi­ral­ing more than 50% on Thurs­day morn­ing, pric­ing in at just un­der $10 apiece.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER